Effects of Pennsaid on Clinical Neuropathic Pain
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01508676 |
|
Recruitment Status :
Completed
First Posted : January 12, 2012
Results First Posted : February 6, 2017
Last Update Posted : February 6, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2 weeks.
The U.S. Food and Drug Administration (FDA) has approved Pennsaid to treat osteoarthritis (bone pain), but the FDA has not approved Pennsaid to treat neuropathic (nerve) pain.
The research study will compare Pennsaid to placebo.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Neuralgia Postherpetic Neuralgia Reflex Sympathetic Dystrophy Complex Regional Pain Syndrome (CRPS) | Drug: Pennsaid Drug: Placebo (2.3% DMSO solution) | Not Applicable |
The research study will compare Pennsaid to placebo. The placebo looks like Pennsaid, but it doesn't contain any Pennsaid. The investigators use placebos in research to see if the results are due to the study drug or to other reasons. At some time during the study the investigators will give the patient Pennsaid. At another time, the investigators will give the patient placebo. The investigators are using Quantitative Sensory Testing (QST), which is temperature testing before and after using the study drug to see if Pennsaid is helpful in reducing people's nerve pain.
In this test, a small metal plate, about the size of a matchbox, is put on the area where the patient has pain. The plate is connected to a computer that can warm or cool the plate. The patient will use a computer mouse button to tell us when the plate feels warm. The QST machine is approved by the Food and Drug Administration (FDA). It is often used by nerve doctors to see if a person has neuropathy (pain caused by damage to a nerve).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 35 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Official Title: | Effects of Pennsaid on Clinical Neuropathic Pain |
| Study Start Date : | November 2011 |
| Actual Primary Completion Date : | March 2013 |
| Actual Study Completion Date : | January 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Pennsaid Phase I
Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
|
Drug: Pennsaid
Other Names:
|
|
Placebo Comparator: Placebo Phase I
Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
|
Drug: Placebo (2.3% DMSO solution)
Other Name: Placebo (2.3% DMSO solution; 20-40 drops; 2-4 times daily). |
- VAS After Treatment [ Time Frame: 2 weeks. ]
Subjects rated their pain using the Visual Analog Scale after a 2 week phase of using pennsaid lotion and after a 2 week phase of using placebo lotion.
The Visual Analog Scale is subject reported on a scale of 0-10 with 0 being no pain, and 10 being the worst pain they can imagine. Results reported are an average of reported VAS scores for the 28 subjects who completed both phase I and phase II of the study.
- Clinical Neuropathic Pain Features- Burning After Treatment [ Time Frame: 2 weeks ]
Subjects rated their "burning pain" using the Visual Analog Scale after a 2 week phase of using pennsaid lotion and after a 2 week phase of using placebo lotion.
The Visual Analog Scale is subject reported on a scale of 0-10 with 0 being no pain, and 10 being the worst pain they can imagine. Results reported are an average of reported VAS scores for the 28 subjects who completed both phase I and phase II of the study.
- Clinical Neuropathic Pain Features- Constant Pain and Hypersensitivity After Treatment [ Time Frame: 2 weeks ]
Subjects rated their "constant pain" and "hypersensitivity" using the Visual Analog Scale after a 2 week phase of using pennsaid lotion and after a 2 week phase of using placebo lotion.
The Visual Analog Scale is subject reported on a scale of 0-10 with 0 being no pain, and 10 being the worst pain they can imagine. Results reported are an average of reported VAS scores for the 28 subjects who completed both phase I and phase II of the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject will be between 18 and 80 years of age.
- Subject has not been on Pennsaid or other topical non-steroid anti-inflammatory drugs for at least one month.
- Subject agrees to make no change in his/her current pain medications during the entire study period. This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.
- Subject has a VAS pain score of 4 or above at the beginning of the study.
- Subject has had a neuropathic pain condition such as those listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.
- Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.
Exclusion Criteria:
- Subject has documented severe liver or renal disease that will affect the elimination of Pennsaid or is subject to the adverse effect of Pennsaid on these organs. (Renal dysfunction is defined as eGFR < 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)
- Subject has pending litigation related to the neuropathic pain condition.
- Subject has active skin lesion or open wound at the site of Pennsaid application (e.g., active shingles with skin lesions).
- Subject is pregnant or lactating.
- Subject has scar tissue or sensory deficit at the site of QST.
- Subject is allergic to diclofenac or has cross-sensitivity to other non-steroid anti-inflammatory drugs.
- Subject has a positive urine (illicit) drug test.
- Subjects who experience asthma, urticaria or an allergic type reaction when taking aspirin or NSAIDs.
- Subjects undergoing coronary artery bypass surgery.
- Subject with a known history of cardiovascular disease, ulcer, gastrointestinal bleed or impaired renal function.
- Subjects currently using NSAIDS.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01508676
| United States, Massachusetts | |
| MGH Center for Translational Pain Research | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | Jianren Mao, M.D., Ph.D. | DACCPM |
| Responsible Party: | Jianren Mao, MD, PhD, Vice Chair Research, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT01508676 History of Changes |
| Other Study ID Numbers: |
2011p000897 |
| First Posted: | January 12, 2012 Key Record Dates |
| Results First Posted: | February 6, 2017 |
| Last Update Posted: | February 6, 2017 |
| Last Verified: | December 2016 |
Keywords provided by Jianren Mao, MD, PhD, Massachusetts General Hospital:
|
neuropathic pain postherpetic neuralgia complex regional pain syndrome reflex sympathetic dystrophy |
Additional relevant MeSH terms:
|
Neuralgia Neuralgia, Postherpetic Complex Regional Pain Syndromes Reflex Sympathetic Dystrophy Pain Neurologic Manifestations Nervous System Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Signs and Symptoms Autonomic Nervous System Diseases Pharmaceutical Solutions |
Anti-Inflammatory Agents Diclofenac Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |